Asia Pacific Conferences heartily welcomes you to the most prestigious International Conference on Pulmonology & Interdisciplinary Medicine during October 12-13,2020 Perth, Australia
Conference series welcomes Pulmonology & Interdisciplinary Medicine specialists across the globe to discuss current trends in Pulmonology & Interdisciplinary Medicine to diagnosis, treatment and management .strategic sessions of the pulmonary & Interdisciplinary Medicine covering about almost all of the pulmonology Diseases such as COPD, Asthma, Allergy, Cystic fibrosis, pneumonia, tuberculosis, emphysema, Lung nodules, chronic cough ,mycobacterial infection ,influenza ,Bronchiectasis, etc.
The PULMONARY 2020 conference composed of well –organized scientific sessions ,plenary sessions, oral presentation, poster presentation , one to one meetings ,networking sessions, e-poster presentation ,young Research Forums ,B2B meetings ,international workshops ,symposiums, Industrial sessions, Exhibitor presentation etc.
Who Should Attend?
Pulmonary 2020 welcomes the multidisciplinary medical professionals, clinicians, and researchers associated with the diagnosis, treatment associated with the diagnosis, treatment and management of respiratory diseases and allied fields. This pulmonology congress is the best platform that would help the pulmonologists and Respiratory care professionals to get the insights and latest trends to improve the patient care. All the researchers working in the field of Pulmonology, Interdisciplinary Medicine, Asthma, Pneumonia, emphysema, tuberculosis, COPD, lungs diseases, Lung Cancer, complicated chest infections and other allied fields will be of interest. The Scope of this pulmonary conference is for the below professionals, but not limited to:
- Respiratory medicine
- Respiratory physicians
- Respiratory disease specialists
- Allergy and Immunology
- General Medicine & Internal Medicine
- Respiratory Therapy
- Radiology & Radiotherapy
- Behavioral Science
- Environmental and Occupational Health
- Infectious Disease
- Pediatric Pulmonary, Critical Care and Sleep
By attending the Pulmonary 2020, October 12-13, 2020 Perth, Australia can get the insights of:
- Recent trends & techniques of pulmonology medicine
- Upgrade yourself with latest innovations to optimize the treatment process of pulmonology Diseases
- Discuss the current challenges & update with future opportunities in improving respiratory care in future era
- Assess the treatment gaps of various pulmonary & Respiratory diseases
- Update yourself with new strategies of diagnosing Sleep Apnea, Asthma, Allergy, COPD and other related diseases and define the new treatment strategies
- Review the efficacy of spirometer access of breathing partten and to identify various disease conditions like Asthma, COPD, pulmonary fibrosis, cystic fibrosis and to optimize the non-invasive mechanical ventilation process in case of respiratory failure.
Abstract Eligibility Criteria
- Individuals may submit up to two regular abstracts as the first author.
- Individuals may submit an unlimited number of Trials in Progress abstracts.
- Individuals may serve as a co-author on an unlimited number of abstracts.
- All types of Pulmonologists, Thoracic Surgeon’s, Medicinal, Health research are eligible for submission.
- Abstract should address scientific questions, detail clinical observations, or contain primary scientific data.
- Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.
- Interim analysis of a prospective randomized clinical trial will be considered if it is performed as planned in the original protocol and is statistically valid.
- Abstracts of clinically-related subjects should be combined into a single abstract.
Note: Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts.
Provide your full name, academic degree(s), institution, address, and email address and recent photograph. You will receive all future correspondence from us regarding the status of your abstract.
The selected abstracts will be published in Conference Proceedings.
Early Bird Discount Registration Offer: On/Before January 30, 2020
Early Bird Abstract Submission Date: February 25, 2020
Abstract Submission Deadline: March 15, 2020
Speaker Presentations Sessions and Time limits:
Keynote Speech 40-45 Minutes,
Workshop/Symposium 60 Minutes
Plenary Speech 20-25 Minutes,
Poster Presentation 10-15 Minutes
Track 1 : Pulmonary hypertension
Pulmonary hypertension is a type of high blood pressure that affects the arteries in lungs and the right side of heart. In one form of pulmonary hypertension, tiny arteries in lungs, called pulmonary arterioles, and capillaries become narrowed, blocked or destroyed. This makes it harder for blood to flow through lungs, and raises pressure within lungs' arteries. As the pressure builds, the heart's lower right chamber (right ventricle) must work harder to pump blood through the lungs, eventually causing heart muscle to weaken and fail.
Pulmonary Hypertension defined as a pulmonary arterial pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during exercise, is often characterized by a progressive and sustained increase in pulmonary vascular resistance that eventually may lead to right ventricular failure. It can be a life-threatening condition if untreated. Therapy for Pulmonary Hypertension is targeted at the underlying cause and its effects on the cardiovascular system.
Physicians may recommend tests and procedures to diagnose Pulmonary Hypertension and discover its cause and severity. Common diagnostic tests include an echocardiograph, chest X-ray, electrocardiogram (EKG) and catheterization of the right heart. Discovering the underlying cause may involve a chest CT scan, chest MRI, lung function tests, (PSG), lung ventilation/perfusion scan and blood tests.
- Pulmonary arterial hypertension
- lung disease
- left-sided heart disease
- Blood disorders
- Complications for Pneumonia
Track 2 : Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a type of chronic scarring lung disease characterized by a progressive and irreversible decline in lung function. Symptoms typically include gradual onset of shortness of breath and a dry cough. Other changes may include feeling tired and abnormally large and dome shaped finger and toenails Complications may include pulmonary hypertension heart failure, pneumonia, or pulmonary embolism. The cause is unknown. Risk factors include cigarette smoking, certain viral infections, and a family history of the condition. The underlying mechanism involves scarring of the lungs. Diagnosis requires ruling out other potential causes. It may be supported by a CT scan or lung biopsy which show usual interstitial pneumonia. It is a type of interstitial lung disease.
- Signs and symptoms for Idiopathic pulmonary fibrosis
- Causes for Idiopathic pulmonary fibrosis
- Pathogenesis of Idiopathic pulmonary fibrosis
- Diagnosis for Idiopathic pulmonary fibrosis
- Treatment for Idiopathic pulmonary fibrosis
Track 3: Pulmonary rehabilitation
Pulmonary rehabilitation is also known as respiratory rehabilitation, is an important part of the management and health maintenance of people with chronic respiratory disease who remain symptomatic or continue to have decreased function despite standard medical treatment. It is defined by the American Thoracic Society and the European Respiratory Society as an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities. In general, pulmonary rehabilitation refers to a series of services that are administered to patients of respiratory disease and their families, typically to attempt to improve the quality of life for the patient.
- Where Is Pulmonary Rehabilitation Administered?
- Can Use Oxygen during Pulmonary Rehabilitation?
- Can Do Pulmonary Rehabilitation at Home?
- How Much Does Pulmonary Rehabilitation Cost?
Track 4 : Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease is a group of progressive lung diseases. The common are emphysema and chronic bronchitis. Many people with COPD have both of these conditions. Emphysema slowly destroys air sacs in lungs, which affects with external air flow. Bronchitis causes inflammation and narrowing of the bronchial tubes, which permits mucus to form. It also includes asthma and certain forms of bronchiectasis. COPD makes it harder to breathe. Indications may be mild at initial stage with cough and shortness of breath. As it progresses, it can become increasingly difficult to breathe. COPD Conferences focus on the modern approaches of Pulmonology.
COPD is a chronic inflammatory lung disease it causes obstructed airflow from the lungs. Chronic obstructive pulmonary disease Symptoms includes breathing difficulty, cough, mucus (sputum) production and wheezing. Chronic obstructive pulmonary disease caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke.
Emphysema and chronic bronchitis are the two most common conditions that contribute to chronic obstructive pulmonary disease. Most instances of pulmonary diseases can be prevented by lessening presentation to hazard factors this incorporates diminishing rates of smoking and enhancing indoor and open air quality. While treatment can moderate declining, no cure is known.
Medications incorporate halting smoking, inoculations, respiratory recovery, and regularly breathed in bronchodilators and steroids. A few people may profit by long haul oxygen treatment or lung transplantation. In the individuals who have times of intense compounding, expanded utilization of prescriptions and hospitalization might be required.
- What is COPD?
- What are the symptoms and causes of COPD?
- Diagnosing and Treatment for COPD
- Medications for COPD
- Diet recommendations for people with COPD
Track 5: COPD Pathogenesis
Inflammation is present in the lungs, especially the small airway routes, of all people who smoke. COPD Pathogenesis is typical defensive reaction to the inhaled toxins is enhanced in COPD, leading to tissue destruction, debilitation of the defence mechanisms and interruption of the repair mechanisms. In general, the inflammatory and structural changes in the airway routes increased with disease seriousness and hold on even after smoking cessation. Other than inflammation, two different procedures are associated with the pathogenesis of COPD—an irregularity amongst proteases and ant proteases and an imbalance amongst oxidants and antioxidants agents in the lungs. Pulmonary Conferences expresses various developing treatments for COPD.
- Airway inflammation
- Mucociliary dysfunction
- Mucociliary dysfunction Protease imbalance
- Antiprotease imbalance
Track 6 : Asthma and Allergy
Asthma and Allergy is asthma caused by an allergic reaction. It’s also known as allergy-induced asthma. Allergic asthma is the most common type of asthma. About 90% of kids with childhood asthma have allergies, compared with about 50% of adults with asthma. The symptoms that go along with allergic asthma show up after you breathe things called allergens like pollen, dust mites, or mold. Because allergens are everywhere, it's important that people with allergic asthma know their triggers and learns how to prevent an attack. During asthma, when the airway comes into contact with a trigger, the linings of the airway become inflamed and narrow. Mucus clogs and tightens the airways, making it difficult for someone having the breath.
- What is allergic asthma?
- What are the causes of allergic asthma?
- What are the symptoms of allergic asthma?
- How is allergic asthma diagnosed?
- What are the treatments for allergic asthma?
- What are the potential complications of allergic asthma?
Aspiratory implies the field of drug identifying with lung and respiratory issue. Working with general pediatrics, respiratory pediatricians treat an extensive variety of pneumonic issue. Aspiratory implies the field of solution identifying with lung and respiratory issue. Working with general pediatrics, respiratory pediatricians treat an extensive variety of pneumonic issue. It incorporates Asthma, Sleep Disorder, Chronic Cough, Exercise initiated Asthma, Congenital Lung Problem and Pediatric Pneumonia.
A great part of the focal point of aspiratory recovery, look into and pneumonic solution goes toward the most youthful individuals from society-the babies. It's inherent however treatable. With a sound aspiratory stenosis finding the heart valve can be supplanted or repaired and kids can develop to lead ordinary solid lives. Rest apnea influences untimely infants. A circumstance called apnea of rashness exists when the tyke doesn't breath for 20 seconds or more. It's a pneumonic illness that can be treated with ventilation machines and medicines. Gratefully, most untimely youngsters become out of it when they reach three years.
- Expertise in the full range of pediatric respiratory conditions
- Advanced diagnostic capabilities
- Innovative respiratory disease research
Track 8 : Interstistial Lung Disease
Lung cancer is a condition that causes cells to divide in the lungs uncontrollably. This causes the growth of tumors that reduce a person's ability to breathe. In lung cancer, this pattern of cell overgrowth occurs in the lungs, which are vital organs for breathing and gas exchange. Cigarette smoking is the principal risk factor for development of lung cancer, Passive exposure to tobacco smoke (passive smoking) also can cause lung cancer in non-smokers. The two types of lung cancer, which grow and spread differently, are small-cell lung cancers (SCLC) and non-small-cell lung cancers (NSCLC). Medical professionals also refer to them as small-cell lung carcinoma and non q-small-cell lung carcinoma.
The stage of lung cancer refers to the extent to which the cancer has spread in the body. Treatment of lung cancer can involve a combination of surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy as well as newer experimental methods. The general prognosis of lung cancer is poor because doctors tend not to find the disease until it is at an advanced stage. Five-year survival is around 54% for early stage lung cancer patients that have a tumor localized to the lungs, but only around 4% in those with advanced, inoperable lung cancer. Smoking cessation is the most important measure that can prevent the development of lung cancer.
- What are the causes of interstitial lung disease?
- Diagnosis for Interstitial lung disease
- Risk factors for interstitial lung disease
Track 9 : lung transplantation
lung transplantation is a surgical procedure in which a patient's diseased lungs are partially or totally replaced by lungs which come from a donor. Donor lungs can be retrieved from a living donor or a deceased donor. A living donor can only donate one lung lobe. With some lung diseases, a recipient may only need to receive a single lung. With other lung diseases such as cystic fibrosis, it is imperative that a recipient receive two lungs. While lung transplants carry certain associated risks, they can also extend life expectancy and enhance the quality of life for end-stage pulmonary patients.
Lung damage can often be treated with medication or with special breathing devices. But when these measures no longer lung function becomes life-threatening, doctor might suggest a single-lung transplant or a double-lung transplant. Some people with coronary artery disease may need a procedure to restore blood flow to a blocked or narrowed artery in the heart, in addition to a lung transplant. In some cases, people with serious heart and lung conditions may need a combined heart-lung transplant
- Risks factors for Lung transplantation
- Types of lung transplant
- Factors that may affect the eligibility for a lung transplant
- Side effects of anti-rejection drugs
- Transplant requirements
Track 10 : Pneumonia
Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus (purulent material), causing cough with phlegm or pus, fever, chills, and difficulty breathing. A variety of organisms, including bacteria, viruses and fungi, can cause pneumonia. Pneumonia is an inflammatory condition of the lung affecting primarily the small air sacs known as alveoli. Typically symptoms include some combination of productive or dry cough, chest pain, fever, and trouble breathing.
Pneumonia is usually caused by infection with viruses or bacteria and less commonly by other microorganisms, certain medications and conditions such as autoimmune diseases. Risk factors include cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, diabetes, heart failure, a history of smoking, a poor ability to cough such as following a stroke, and a weak immune system. Diagnosis is often based on the symptoms and physical examination. Chest X-ray, blood tests, and culture of the sputum may help confirm the diagnosis. The disease may be classified by where it was acquired with community, hospital, or health care associated pneumonia
- Signs and symptoms of Pneumonia
- Cause for Pneumonia
- Risk factors for Pneumonia
- Diagnosis for Pneumonia
- Prevention for Pneumonia
- Spirometry is a noninvasive test to assess lung function. During the test, you’ll take a deep breath and then blow into a tube connected to the spirometer.
- 2. Imaging tests include a chest X-ray or CT scan. These images can provide a detailed look at your lungs, blood vessels, and heart.
- 3. An arterial blood gas test involves taking a blood sample from an artery to measure blood oxygen, carbon dioxide, and other important levels.
- Smoking cessation: The most essential step in any treatment plan for COPD is to stop all smoking. It's the only way to keep COPD from getting defective which can eventually reduce ability to breathe.
- Bronchodilators: These medications which usually come in an inhaler relax the muscles around airways. This can help relieve coughing and shortness of breath and make breathing easier.
- Inhaled steroids: Inhaled corticosteroid medications can reduce airway inflammation and help prevent exacerbations. Side effects may include bruising, oral infections and hoarseness. These medications are useful for people with frequent exacerbations of COPD.
- Phosphodiesterase-4 inhibitors: A new type of medication approved for people with severe COPD and symptoms of chronic bronchitis is roflumilast a phosphodiesterase-4 inhibitor. This drug decreases airway inflammation and relaxes the airways.
- Antibiotics: Respiratory infections, such as acute bronchitis, pneumonia and influenza, can aggravate COPD symptoms. Antibiotics help treat acute exacerbations, but they aren't generally recommended for prevention.
- Oxygen therapy: There are several devices to deliver oxygen to the lungs, including lightweight, portable units that you can take with you to run errands and get around town. Some people with COPD use oxygen only during activities or while sleeping. Others use oxygen all the time. Oxygen therapy can improve quality of life and is the only COPD therapy proven to extend life
- Pulmonary rehabilitation program: These programs generally combine education, exercise training,
Track 12 : Emphysema
Emphysema is a type of COPD involving damage to the air sacs (alveoli) in the lungs. As a result, your body does not get the oxygen it needs. Emphysema makes it hard to catch your breath. You may also have a chronic cough and have trouble breathing during exercise. The most common cause is cigarette smoking.
- fast heartbeat
Track 13 : Respiratory framework
Respiratory framework conveying air to the lungs and taking oxygen to the body and discharging carbon dioxide back in to the air. Respiratory framework is the human life structures of respiratory organ this framework made up of Lungs.
- TEACH KIDS SMOKING STINKS
- COVER YOUR COUGHS
- CONVERT YOUR FIREPLACE
- WHAT IS THE RESPIRATORY SERVICE FRAMEWORK
Track 14 : Lung Homeostasis
Pulmonary immune homeostasis is maintained by a network of tissue-resident cells that continually monitor the external environment, and in health, instruct tolerance to innocuous inhaled particles while ensuring that efficient and rapid immune responses can be mounted against invading pathogens. Here we review the multiple pathways that underlie effective lung immunity in health, and discuss how these may be affected by external environmental factors and contribute to chronic inflammation during disease. In this context, we examine the current understanding of the impact of the microbiota in immune development and function and in the setting of the threshold for immune responses that maintains the balance between tolerance and chronic inflammation in the lung. We propose that host interactions with microbes are critical for establishing the immune landscape of the lungs.
- Influence of Age
- Immune System
Track 15 : Influenza
Influenza is an infectious disease caused by an influenza virus.Symptoms can be mild to severe. The most common symptoms include, high fever, runny nose, sore throat, muscle and joint pain, headache, coughing, and feeling tired. These symptoms typically begin two days after exposure to the virus and most last less than a week. The cough, however, may last for more than two ,weeks In children, there may be diarrhea and vomiting, but these are not common in adults.Diarrhea and vomiting occur more commonly in gastroenteritis, which is an unrelated disease and sometimes inaccurately referred to as "stomach flu" or the "24-hour flu"Complications of influenza may include viral pneumonia, secondary bacterial pneumonia, sinus infections, and worsening of previous health problems such as asthma or heart failure.
- breathing difficulties
- pain or pressure in the chest or abdomen
- dizziness, confusion, or loss of alertness
- severe pain, weakness, and unsteadiness
a worsening of other existing health conditions
Track 16 : Pediatric and Geriatric Gastroenterology
Digestive disorders are common in children due to lack of Nutrition with the symptoms like abdominal pain etc. GIT and Brain are closely connected and functional conditions are due to a combination of extra sensitivity of the GI tract, with changes in the motility or movement of the digestive system. Our stomachs and intestines are moving food all the time and some people feel this more intensely than other people. Paediatric hepatologists provide both tertiary and national hepatology services in designated centres. They diagnose and manage paediatric liver diseases, such as acute and chronic liver failure and are co-located with transplant services to provide care for liver and small bowel transplantation patients. They understand the indications, benefits and risks of procedures for diagnostic evaluation and possess specialised skills in performing and interpreting the results of tests, such as gastrointestinal endoscopy and liver biopsy.
Gastro esophageal Reflux Disease
Track 17 : Pulmonary Physiology
Pulmonary Physiology is the progression of oxygen from the outside condition to the cells inside tissues, and the vehicle of carbon dioxide the other way. The physiological significance of breath contrasts from the biochemical definition, which suggests a metabolic methodology by which an animal gets essentialness by oxidizing supplements and releasing waste things. Though physiologic breath is critical to help cell breath the techniques are specific. Cell breath occurs in individual cells of the living being, while physiologic breath concerns the scattering and transport of metabolites between the living thing and the external condition. Pulmonary Physiology is the progression of oxygen from the outside condition to the cells inside tissues, and the vehicle of carbon dioxide the other way. The physiological significance of breath contrasts from the biochemical definition, which suggests a metabolic methodology by which an animal gets essentialness by oxidizing supplements and releasing waste things. Though physiologic breath is critical to help cell breath the techniques are specific. Cell breath occurs in individual cells of the living being, while physiologic breath concerns the scattering and transport of metabolites between the living thing and the external condition.
The Respiratory System
Mechanics of Breathing
Ventilation and Carbon Dioxide Elimination
Pulmonary Blood Flow
Control of Breathing
The global respiratory drugs market size will grow by USD 17.67 billion during 2018-2022. This industry research report provides a detailed analysis of the market based on type (asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, cystic fibrosis, idiopathic pulmonary fibrosis, and other respiratory disorders.
The increase in incidences and prevalence of respiratory disorders is driving global respiratory drugs market. Several types of respiratory diseases such as COPD, asthma, and acute respiratory infections are on the rise causing major mortality and disease burden on patients. Moreover, respiratory diseases account for more than millions of deaths in developing countries with a high number of cases reported for children. This created the need for management and treatment of respiratory diseases, which in turn, drives the respiratory drugs market.
The respiratory care devices market is segmented into three major end user segments—hospitals, home care settings, and ambulatory care centers. In 2019, hospitals accounted for the largest market share of the market, mainly because of their financial capabilities, which allow them to purchase high-priced instruments and the availability of trained professionals to operate these instruments have ensured the high share of hospitals in this market. Home care settings are expected to witness the highest growth during the forecast period, mainly due to the development of compact and lightweight respiratory care devices that are easier to carry and operate.
Past Conference Report
Pulmonary Disorders 2018
Pulmonary Disorders - 2017
We would like to thank all of our wonderful speakers, conference attendees, students, associations and guests for making Pulmonary Disorders 2017 a wonderful event.
International Conference on Pulmonology and Critical Care Medicine was organized by Conference Series LLC, during April 24-25, 2017 in Las Vegas, USA. We successfully hosted the event at the conference venue. Active participation and generous response were received from the Organizing Committee Members, Editorial Board Members of respective Journals, scientists, researchers, as well as experts from Pulmonologist and students from diverse groups who made this conference as one of the most successful and productive events in 2017 from Conference Series LLC. It was the world’s meeting that is dedicated to Pulmonary, Heart, Critical Care and Respiratory.
The conference was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 35 countries, who have driven this event into the path of success.
The conference was initiated with a warm welcome note from Honourable guests and the Keynote forum lead by Dr. Shahid Sheikh, Principal Investigator, Associate, Professor Ohio State University College of Medicine USA honourable Moderator for the conference.
Various sessions were carried out with multiple presentations from speakers all around the world. Major Sessions to be discussed were:
· Pulmonary Diseases and Disorders
· Symptoms and Comorbid
· Pulmonary Function Testing and Diagnosis
· Asthma and Related Disorders
· Bronchiectasis and Atelectasis
· COPD and Related Disorders
· Pulmonary Vascular Disease
· Diffuse Alveolar Hemorrhage
· Environmental Pulmonary Diseases
· Lung Diseases
· Pulmonary Embolism
· Pulmonary Research
· Pulmonary Rehabilitation
· Critical Care Medicine
· Novel Approach and Therapies
The conference witnessed an amalgamation of peerless speakers, who enlightened the crowd with their enviable research knowledge and on various alluring topics related to the field of Pulmonary and Critical Care, carried out through various scientific sessions and plenary lectures:
Pulmonary rehabilitation aKnde ythne ocatnec eFr osertutinmg: Is it beneficial? Is it safe? by Dr. Vickie R Shannon, The University of Texas MD Anderson Cancer Center, USA
Wheezing in Infancy. When to treat and why? by Dr. Shahid Sheikh, Ohio State University College of Medicine, USA
Respiratory management of the newborn with an Omphalocele by Dr. Joanne Baerg, Loma Linda University Medical Center, USA
The distinct roles of circulating monocytes and alveolar macrophages in mouse model with acute lung injury by Dr. Zhilong Jiang, Fudan University, PR China
The Role of Traumatic Pneumonectomy by Dr. Bradley J Phillips, Creighton University School of Medicine, USA
Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo by Dr. Donald Davidson, University of Edinburgh, UK
Difficult to Control Pediatric Asthma (co-morbidities) by Dr. Shahid Sheikh, Ohio State University College of Medicine, USA
With the unique feedbacks from the conference, Conference Series LLC announced the commencement of the 8th International Conference on Pulmonology and Critical Care Medicine
March 20 - 21, 2018 in Orlando, USA. With the support and contribution of the Organizing Committee Members, we successfully hosted the “Pulmonary Disorders 2017” at the conference venue. Hence, we look forward to see your benign presence with active contribution and support to make Pulmonary Disorders 20178successful once more.
Asia Pacific Conferences heartily welcomes you to the most prestigious International Conference on Pulmonology & Interdisciplinary Medicine during October 12-13,2020 Perth, Australia
Past Reports Gallery
All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.
Abstracts will be provided with Digital Object Identifier by